Please assess the completion status of the following clinical trial:

Trial Title: Phase I Biomarker Study (BMS-936558)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com~Inclusion Criteria:~* Women and men ≥ 18 years of age.~* Histologic confirmation of renal cell carcinoma with a clear cell component.~* Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST).~* Tumor sites that can be accessed for repeat biopsies at acceptable clinical risk.~* Previously treated subjects must have failed at least 1 prior anti-angiogenic agent and can have a maximum of 3 prior systemic treatments for renal cell cancer.~* Subjects in the treatment naive arm cannot have received prior systemic therapy for their renal cell carcinoma.~Exclusion Criteria:~* Active or progressing brain metastases.~* Active concomitant.~* Active or history of autoimmune disease.~* Active use of systemic corticosteroids.~* Prior therapy with Cytotoxic T lymphocyte-associated antigen 4 (anti-CTLA4), anti Programmed death-1 (anti-PD1), anti Programmed death ligand 1 (anti-PD-L1), anti Programmed death ligand 2 (anti-PD-L2), anti-CD137, anti-CD40, anti-OX40 antibodies.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1: BMS-936558 (Type: EXPERIMENTAL): None
- Arm 2: BMS-936558 (Type: EXPERIMENTAL): None
- Arm 3: BMS-936558 (Type: EXPERIMENTAL): None
- Arm 4: BMS-936558 (Type: EXPERIMENTAL): (treatment naive)

Based on this trial design, predict the completion outcome and termination type (if applicable).